Skip to content

An exploratory study about cryoablation combined with pelvic lymphadenectomy by laparoscopy and urethroscopy for bladder preservation strategies of high risk (T1G3) and myometrial invasive bladder cancer

An exploratory study about cryoablation combined with pelvic lymphadenectomy by laparoscopy and urethroscopy for bladder preservation strategies of high risk (T1G3) and myometrial invasive bladder cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030355
Enrollment
Unknown
Registered
2020-02-29
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

experimental group:TURBT, cryoablation and PLND
control group:radical cystectomy, PLND and urinary diversion

Sponsors

Huashan Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: For Experimental Arm I 1. High grade T1 or localized muscle-invasive(T2-T4a)bladder cancer confirmed by pathological evidence; 2. The number of tumor sites is no more than 5; 3. Male or female, aged 18 to 85 years; 4. Intention for bladder-sparing or unfit for radical cystectomy; 5. Patients will sign written informed consent and comply with follow-up, treatment and examination during the study. For Experimental Arm II 1. High grade T1 or localized muscle-invasive(T2-T4a)bladder cancer confirmed by pathological evidence; 2. The number of tumors sites is no more than 5; 3. Male or female, aged 18 to 85 years; 4. Patients will sign written informed consent and comply with follow-up, treatment and examination during the study.

Exclusion criteria

Exclusion criteria: 1. Patients with known allergic reaction to adjuvant immunotherapy; 2. Patients with severe infectious diseases such as bacteremia and toxemia; 3. Patients who have severe coagulopathy; 4. Patients are suffering from severe heart, brain, lung, liver, kidney diseases, that cannot tolerate the surgery; 5. Patients are suffering from other malignant tumors; 6. Pregnant or lactating women; 7. Patients with contraindication for cystoscopy, eg. severe urethral stricture; 8. Patients with contraindication of either systemic chemotherapy or immunotherapy; 9. Patients are enrolled in any other concurrent trial; 10. Patients who have any other conditions that are not appropriate for the clinical trial.

Design outcomes

Primary

MeasureTime frame
overall survival;progression-free survival;

Secondary

MeasureTime frame
Local recurrence rate;quality of life;

Countries

China

Contacts

Public ContactHaowen Jiang

Department of Urology, Huashan Hospital affiliated to Fudan University

oncouro_jhw@126.com+86 13003255733

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026